Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT02784496
Phase
PHASE2
Status
Completed

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Long-term Follow-up — OTHER
    Undergo follow-up assessment
  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Ruxolitinib — DRUG
    Given PO

Study Details

This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.

Key Dates

Start date
Sep 29, 2016
Status verified
Aug 2025
Primary completion
Jan 23, 2024
Completion
Jan 23, 2024

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ruxolitinib, follow-up)
    Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.

Primary Outcome Measure

Most Common Treatment Related Adverse Events [ Time Frame: to the date of failure or death from any cause, Up to 7 years, 3 months and 24 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
M D Anderson Cancer Center· Houston, TX

Related Studies